Live webinarSat, Jul 4, 8 PM ESTRegister →
NAPPA
North America Pharmaceutical Professional Alliance

Connecting global biopharma to partnerships that matter.

NAPPA is a global biopharma alliance connecting companies, investors, scientists, and industry leaders across North America, Europe, Asia-Pacific, and other key innovation hubs to enable high-impact partnerships, licensing opportunities, and cross-border collaboration.

Explore partnerships Become a member
Upcoming event
NAPPA Healthcare & Biopharma Insights Episode 1

COINS Act & BINSA: What Chinese Biopharma Leaders Need to Know

An in-depth analysis of the COINS Act and BINSA and their implications for innovation, licensing, investment, and global collaboration.

View details & register →
What we do

Execution-focused support across the biopharma lifecycle.

01

BD & Capital

Cross-border partnerships, strategic licensing, M&A, and the creation of new ventures.

02

R&D Enablement

Connecting innovators with preclinical and clinical development expertise, and CRO/CDMO partners.

03

Market Access

Strategic guidance on U.S.–China regulatory pathways and commercialization support.

04

Talent & Network

High-level talent matching and a curated global industry exchange for members.

The NAPPA model

Credibility meets delivery.

Many cross-border partnerships struggle to move beyond introductory conversations. NAPPA is structured to fix that: a non-profit platform that builds trust and ecosystem connections, paired with a commercial arm that takes high-value projects across the finish line.

How it works
Track 1

Non-profit platform

Ecosystem building, advisory access, and seamless resource connection across NAPPA's global network.

Track 2

Commercial arm

Efficient execution of complex, high-value cross-border projects — from BD diligence through deal close.

Advisory framework

Four pillars determine a platform's ceiling.

Scientific capability, industry experience, and capital acumen — they only deliver outcomes when they coexist. NAPPA's advisory board is structured around the four dimensions cross-border execution actually requires.

01

Science

Xumu Zhang
Dean, Medi-X Institute, SUSTech
02

Drug R&D

Dr. Mann Fung
Former CEO, Tavotek Biotherapeutics
03

Industry Translation

Qin Chao Lu
Founding Partner, Danlu Capital
04

Capital

Xin Sylvia He, PhD
Managing Partner, Hyfinity Investments
Meet the full advisory board →
Latest

News & Events

See all news →
Event

Open registration: COINS Act & BINSA webinar with Frank Gao, July 4

NAPPA's Healthcare & Biopharma Insights series opens on July 4 with a one-hour briefing on the COINS Act, BINSA, and their implications for Chinese biopharma.

Read more →
Event

Open call: 1st Industry–Academia–Research–Medicine Innovation & Entrepreneurship Competition

NAPPA is co-organizing a global innovation competition that connects scientists, clinicians, and biotech founders with China's biopharma industry, clinical networks, and capital.

Read more →
Appointment

NAPPA appoints Attorney Zhihua Duan as Regional Director, Beijing–Tianjin

A cross-border legal and IP specialist joins NAPPA to anchor the alliance's presence across China's northern life-science corridor.

Read more →
Membership

Join NAPPA.

Become part of an execution-driven global network bridging North American innovation with Asia-Pacific industrial scale and capital.

View membership tiers
Individual
$100/year
  • Member-only events & roundtables
  • Newsletter & deal-flow digest
  • Working group participation
  • Member directory access
Company
$500/year
  • Everything in Individual
  • Logo placement on NAPPA channels
  • Partnership & sourcing introductions
  • Listing in licensing/sourcing channels